Show simple item record

dc.contributor.authorBygrave, Helen
dc.contributor.authorFord, Nathan
dc.contributor.authorvan Cutsem, Gilles
dc.contributor.authorHilderbrand, Katherine
dc.contributor.authorJouquet, Guillaume
dc.contributor.authorGoemaere, Eric
dc.contributor.authorVlahakis, Nathalie
dc.contributor.authorTriviño, Laura
dc.contributor.authorMakakole, Lipontso
dc.contributor.authorKranzer, Katharina
dc.date.accessioned2011-09-19T14:06:10Z
dc.date.available2011-09-19T14:06:10Z
dc.date.issued2011-03
dc.identifier.citationImplementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. 2011, 56 (3):e75-8 J. Acquir. Immune Defic. Syndr.en
dc.identifier.issn1944-7884
dc.identifier.pmid21164354
dc.identifier.doi10.1097/QAI.0b013e3182097505
dc.identifier.urihttp://hdl.handle.net/10144/142609
dc.description.abstractThe latest World Health Organization guidelines recommend replacing stavudine with tenofovir or zidovudine in first-line antiretroviral therapy in resource-limited settings. We report on outcomes and toxicities among patients on these different regimens in a routine treatment cohort in Lesotho.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of Acquired Immune Deficiency Syndromes (1999)en
dc.subject.meshAdenineen
dc.subject.meshAdulten
dc.subject.meshAnti-HIV Agentsen
dc.subject.meshAntiretroviral Therapy, Highly Activeen
dc.subject.meshCohort Studiesen
dc.subject.meshFemaleen
dc.subject.meshHIV Infectionsen
dc.subject.meshHumansen
dc.subject.meshLesothoen
dc.subject.meshMaleen
dc.subject.meshPhosphonic Acidsen
dc.subject.meshPregnancyen
dc.subject.meshPregnancy Complications, Infectiousen
dc.subject.meshRural Populationen
dc.subject.meshTreatment Outcomeen
dc.titleImplementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years.en
dc.contributor.departmentMédecins Sans Frontières, Morija, Lesotho. helen.bygrave@joburg.msf.orgen
dc.identifier.journalJournal of Acquired Immune Deficiency Syndromes (1999)en
refterms.dateFOA2019-03-04T08:53:15Z
html.description.abstractThe latest World Health Organization guidelines recommend replacing stavudine with tenofovir or zidovudine in first-line antiretroviral therapy in resource-limited settings. We report on outcomes and toxicities among patients on these different regimens in a routine treatment cohort in Lesotho.


Files in this item

Thumbnail
Name:
Bygrave et al Tenofovir First ...
Size:
135.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record